ValuEngine upgraded shares of Momenta Pharmaceuticals (NASDAQ:MNTA) from a hold rating to a buy rating in a research report released on Thursday morning.
Several other brokerages have also recently weighed in on MNTA. BidaskClub upgraded shares of Momenta Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Saturday, July 14th. Cantor Fitzgerald set a $24.00 price target on shares of Momenta Pharmaceuticals and gave the stock a hold rating in a research report on Monday, October 1st. Stifel Nicolaus restated a buy rating and issued a $40.00 price target on shares of Momenta Pharmaceuticals in a research report on Wednesday, October 10th. Finally, Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a hold rating to a buy rating and set a $18.00 price target on the stock in a research report on Monday, October 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $29.25.
Shares of Momenta Pharmaceuticals stock traded down $0.03 on Thursday, hitting $13.63. 21,095 shares of the company traded hands, compared to its average volume of 1,024,614. The stock has a market cap of $1.07 billion, a P/E ratio of -11.25 and a beta of 2.34. Momenta Pharmaceuticals has a 52 week low of $11.72 and a 52 week high of $32.20.
Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.50). Momenta Pharmaceuticals had a negative net margin of 128.49% and a negative return on equity of 40.55%. The company had revenue of $13.00 million for the quarter, compared to the consensus estimate of $15.83 million. During the same quarter in the previous year, the business earned ($0.50) EPS. The company’s quarterly revenue was down 44.9% on a year-over-year basis. Sell-side analysts expect that Momenta Pharmaceuticals will post -2.55 earnings per share for the current fiscal year.
In other Momenta Pharmaceuticals news, Director Elizabeth Stoner sold 4,152 shares of the business’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $27.33, for a total transaction of $113,474.16. Following the transaction, the director now owns 33,791 shares in the company, valued at $923,508.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Craig A. Wheeler sold 1,773 shares of the business’s stock in a transaction on Friday, August 10th. The shares were sold at an average price of $26.06, for a total transaction of $46,204.38. The disclosure for this sale can be found here. Insiders sold 12,589 shares of company stock worth $345,785 in the last 90 days. 4.80% of the stock is currently owned by company insiders.
A number of hedge funds have recently bought and sold shares of MNTA. SG Americas Securities LLC bought a new position in Momenta Pharmaceuticals during the second quarter valued at $108,000. Sawtooth Solutions LLC bought a new position in Momenta Pharmaceuticals during the third quarter valued at $227,000. Pillar Pacific Capital Management LLC bought a new position in Momenta Pharmaceuticals during the third quarter valued at $231,000. Amalgamated Bank increased its position in Momenta Pharmaceuticals by 16.1% during the second quarter. Amalgamated Bank now owns 12,544 shares of the biotechnology company’s stock valued at $257,000 after acquiring an additional 1,739 shares during the last quarter. Finally, Laurion Capital Management LP bought a new position in Momenta Pharmaceuticals during the second quarter valued at $284,000. Institutional investors and hedge funds own 95.93% of the company’s stock.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.
Recommended Story: Day Trading
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.